To examine the mechanism of resistance to fluoroquinolones in Mycobacterium tuberculosis, we selected spontaneous fluoroquinolone-resistant mutants from a susceptible strain, H37Rv, and studied the susceptibilities of these mutants and two fluoroquinolone-resistant clinical isolates (A-382, A-564) to various fluoroquinolones and to isoniazid and rifampin. Furthermore, since mutations within the quinolone resistancedetermining region of the structural gene encoding the A subunit of DNA gyrase are the most common mechanism of acquired resistance, we amplified this region by PCR and compared the nucleotide sequences of the fluoroquinolone-resistant strains with that of the susceptible strain. Fluoroquinolone-resistant mutants of H37Rv appeared at frequencies of 2 ؋ 10 ؊6 to 1 ؋ 10
The incidence of tuberculosis in the United States has undergone a resurgence since the mid-1980s (3, 16) . Unfortunately, the AIDS epidemic has contributed significantly to this increase (2) . Complicating this increasing incidence of tuberculosis have been several outbreaks of infections caused by multidrug-resistant strains of Mycobacterium tuberculosis (6) . In New York City in April 1991, 33 percent of all patients with tuberculosis were infected with M. tuberculosis isolates resistant to one or more antituberculosis agents and 19 percent were infected with isolates resistant to both isoniazid and rifampin (8) .
Fluoroquinolones, such as ciprofloxacin, ofloxacin, and especially sparfloxacin, have potent in vitro activities against M. tuberculosis (9, 17, 19, 21) , including the vast majority of multidrug-resistant clinical isolates (8) . Fluoroquinolones have been demonstrated to have clinical efficacy against tuberculosis in combination with other antituberculosis agents (12, 18, 27) . However, resistance to ciprofloxacin and ofloxacin has appeared in clinical isolates of M. tuberculosis, and in some cases such resistance has been shown to emerge during treatment of patients infected with fluoroquinolone-susceptible strains (4, 12, 22, 27) .
DNA gyrase, the primary target of fluoroquinolone action, consists of two A and two B subunits and catalyzes ATPdependent supercoiling of DNA (29) that is necessary for DNA replication in vivo. High-level resistance to fluoroquinolones in various bacteria has been related to mutations in gyrA, the structural gene of the gyrase A subunit. These mutations are virtually always clustered within a conserved region of the gyrA gene referred to as the quinolone resistance-determining region (QRDR) (7, 10, 11, 20, 24, 30, 32) .
We endeavored to examine the mechanism of resistance to fluoroquinolones in M. tuberculosis both in mutants selected from a susceptible parental strain in the presence of a fluoroquinolone and in two fluoroquinolone-resistant clinical isolates. We studied the frequency of spontaneous fluoroquinoloneresistant mutants and the susceptibilities of such mutants and the clinical isolates to approved and investigational fluoroquinolones and the standard antituberculosis drugs. Furthermore, we examined the nucleotide sequences of the QRDRs from all of these fluoroquinolone-resistant strains and compared them with that of the susceptible laboratory strain. A recent report characterized the gyrA and gyrB genes of M. tuberculosis and identified similar mutations within the QRDR in gyrA in quinolone-resistant strains of M. tuberculosis (25) .
(This study was presented in part at the 32nd Annual Meeting of the Infectious Diseases Society of America, Orlando, Fla., 7 to 9 October 1994 [1] .) tuberculosis resistant to ciprofloxacin (MICs Ͼ2 g/ml), strains A-382 and A-564, were as described below. All strains were grown in Middlebrook 7H9 broth and on Middlebrook 7H10 agar supplemented with 10% oleic acid-albumin-dextrosecatalase (OADC; Difco, Detroit, MI) in 5% CO 2 at 37ЊC.
MATERIALS AND METHODS

Clinical isolates. (i) Isolate A-382.
A 48-year-old male with AIDS and cervical lymphadenitis was found to have caseation necrosis and acid-fast bacilli in a lymph node biopsy specimen. He was treated with rifampin, ethambutol, ciprofloxacin, and clofazimine for presumed Mycobacterium avium complex disease while awaiting the culture result. One month later the cultures of the lymph node as well as of sputum yielded M. tuberculosis, and his treatment regimen was changed to isoniazid, rifampin, and ethambutol. The patient was noncompliant, and his sputum remained smear positive for acid-fast bacilli 3 months later. A year later culture of another lymph node biopsy specimen yielded M. tuberculosis resistant to rifampin. His therapy was changed to isoniazid, ethambutol, pyrazinamide, and ofloxacin. He continued to be noncompliant and was lost to followup. He presented after 14 months with fever and respiratory distress and died 2 weeks later. At this time his sputum (from which isolate A-382 was obtained) and blood cultures were positive for M. tuberculosis. These isolates were resistant to rifampin, isoniazid, and ciprofloxacin.
(ii) Isolate A-564. An 88-year-old woman with symptoms of painful cystitis and pyuria was treated unsuccessfully with several courses of antibiotics, including at least five courses of ciprofloxacin, over a period of 1 year. Subsequently, a urine culture yielded M. tuberculosis A-564, which was resistant to rifampin, isoniazid, and ciprofloxacin. She was treated with isoniazid, rifampin, and pyrazinamide for 18 months with significant resolution of her symptoms. All of her subsequent urine cultures remained negative.
Quinolones. Ciprofloxacin was a gift from Miles, Inc.; ofloxacin was a gift from Ortho Pharmaceuticals; sparfloxacin and five investigational fluoroquinolones, PD127391-0002 (FQ-A), PD117596-0002 (FQ-B), PD117558-0073 (FQ-C), PD138312-0002 (FQ-D), and PD131628-00028 (FQ-E), were gifts from ParkeDavis/Warner-Lambert.
Selection of fluoroquinolone-resistant mutants. Cells of H37Rv were plated onto Middlebrook 7H10 agar containing serially twofold diluted concentrations of ciprofloxacin, ofloxacin, and sparfloxacin ranging from 0.125 to 32 g/ml. The plates were incubated at 37ЊC in 5% CO 2 . The inoculum titer was determined by plating diluted aliquots onto drug-free agar and counting the colonies that grew. The frequency of occurrence of resistant mutants in the culture population was calculated from the numbers of colonies on fluoroquinolone-containing agar plates and the original inoculum titer.
Determination of MICs. Each strain was suspended in saline to the turbidity of a McFarland no. 1 standard and was further diluted 10 3 and 10 6 times. Three drops (ϳ100 l) of each suspension was inoculated onto a quadrant of a Middlebrook 7H10 agar plate with no antibiotic and with serial twofold dilutions of each antibiotic. The H37Rv strain served as a control. The inoculated plates were incubated for 15 days in 5% CO 2 at 37ЊC. The MIC was defined as the lowest concentration of each drug at which Յ1% of the plated cells grew as colonies (28) . Full susceptibility testing was carried out twice.
Isolation of DNA. Chromosomal DNA was isolated by the physical disruption method with a mini-bead beater cell disrupter (15) . Briefly, 100-ml cultures of the M. tuberculosis strains were grown for 7 to 9 days in 7H9 broth, and the cells were harvested by centrifugation at 3,000 ϫ g for 10 min at 4ЊC. The pellet was resuspended in 0.5 ml of homogenization buffer (0.3M Tris [pH 8.0], 0.1 M NaCl 6 mM EDTA). The cell suspensions were transferred to vials containing 0.5-mm-diameter glass beads and were disrupted with a mini-bead beater cell disrupter (Biospec Products, Bartlesville, Okla.). The DNA was extracted with a phenol-chloroform (1:1) solution; this was followed by chloroform-isoamyl alcohol (24:1) extraction and ethanol precipitation. The precipitate was collected by centrifugation and was resuspended in TE buffer (10 mM Tris [pH 8.0], 1 mM EDTA). RNA was removed by treatment with RNase A at 100 g/ml at 37ЊC for 30 min; this was followed by phenol extraction and ethanol precipitation as described above, and the DNA was resuspended in TE buffer.
Amplification of QRDR by PCR. Amplification of the QRDR of gyrA was initially carried out with primers GYR-1 (5Ј-GATGGCCTGAAGCCGGTAC AC) and GYR-2 (5Ј-TGCCATACCTACGGCGATACC) designed from the consensus sequences of known gyrA genes from various bacteria (13, 14) . Later, when the sequence of the gyrA gene of M. tuberculosis became available (25) , new primers flanking its QRDR were used: TBGYR-1 (5Ј-CAGCTACATCGACT ATGCG) and TBGYR-2 (5Ј-GGGCTTCGGTGTGTACCTCAT). PCR amplification was performed in a final volume of 100 l. The mixture contained approximately 1 ng of DNA template, final concentrations of 1.0 M (each) primer (TBGYR-1, TBGYR-2), 200 M (each) deoxynucleoside triphosphate (dATP, dCTP, dGTP, and dTTP; Pharmacia), 10 l of Taq buffer (GibcoBethesda Research Laboratories), and 5.0 U of Taq polymerase (Gibco-Bethesda Research Laboratories). Amplification was performed for 40 cycles (1 min at 94ЊC, 1 min at 60ЊC, and 2 min at 72ЊC) for an expected product of 280 bp. The QRDR of each strain was amplified in two independent reactions.
Sequencing of the PCR product. The DNA product obtained from PCR was purified by passage through resin by using the Wizard DNA clean-up system (Promega). Sequencing of both DNA strands was carried out with T7 DNA polymerase (Sequenase 2.0; United States Biochemicals) by using TBGYR-1 and TBGYR-2 primers. Analyses of nucleotide and derived amino acid sequences were performed by using the PC Gene software (IntelliGenetics, Inc.). Numbering of the amino acid residues was based on the Escherichia coli DNA gyrase A subunit and its gyrA gene.
RESULTS
Selection of quinolone-resistant mutants of M. tuberculosis.
Mutants of parental strain H37Rv resistant to ciprofloxacin, ofloxacin, and sparfloxacin were obtained on 7H10 agar containing 2, 4, and 8 g of each fluoroquinolone per ml. Spontaneous mutants appeared at frequencies of 2 ϫ 10 Ϫ6 to 1 ϫ 10 Ϫ8 (Table 1 ). The highest concentration of each fluoroquinolone at which such spontaneous mutants were obtained was 8 g of ciprofloxacin and ofloxacin per ml and 4 g of sparfloxacin per ml. Single spontaneous quinolone-resistant mutants, mutants CIP-1, OFL-1, and SPL-1, obtained by selection on ciprofloxacin, ofloxacin, and sparfloxacin, respectively, were chosen for further studies.
Susceptibilities of fluoroquinolone-resistant spontaneous mutants and clinical isolates. Susceptibility testing of CIP-1, OFL-1, and SPL-1; their parental strain, H37Rv; and the two clinical isolates of M. tuberculosis, A-382 and A-564, was performed on agar containing isoniazid, rifampin, ciprofloxacin, ofloxacin, sparfloxacin, and the five investigational fluoroquinolones. In comparing the MICs obtained from the two successive susceptibility determinations, in no case did comparable MICs differ by more than 1 dilution. In cases of twofold differences, the lower value is reported in Table 2 . Parental strain H37Rv was susceptible to all fluoroquinolones tested. Ciprofloxacin, sparfloxacin, FQ-A, and FQ-C were the most potent (MICs, 0.25 to 0.5 g/ml) fluoroquinolones against this strain. For all of the fluoroquinolone-resistant strains except SPL-1, ciprofloxacin and ofloxacin MICs were 16 g/ml and sparfloxacin MICs were 4 to 8 g/ml. Strain SPL-1 was marginally less resistant. All of the fluoroquinolone-resistant strains were also cross-resistant to all of the investigational fluoroquinolones (MICs, Ն4 g/ml). In general, however, sparfloxacin and FQ-A exhibited the most potent activities against the panel of five fluoroquinolone-resistant strains. None of the spontaneous fluoroquinolone-resistant mutants displayed resistance to isoniazid or rifampin. The two clinical isolates, however, were resistant to these first-line antituberculosis drugs.
PCR amplification and sequence analysis of the QRDR of the gyrA gene. A 320-bp region of the chromosomal DNA which includes the QRDR of the gyrA gene was amplified from the parental strain and the fluoroquinolone-resistant strains by PCR with primers TBGYR-1 and TBGYR-2. The nucleotide sequences and the deduced amino acid sequences were compared, and the results are summarized in Table 3 
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the Asp residue at position 87 (Asp-87) with Asn or Ala-83 with Val in the A subunit of the mutant DNA gyrase. Mutations at codon 87 leading to Asp3Asn or Asp3Ala replacements were noted in the two fluoroquinolone-resistant clinical isolates. H37Rv and its spontaneous resistant mutants had serine residues at codon 88, whereas the two clinical isolates had threonine residues at that position.
DISCUSSION
Spontaneous fluoroquinolone-resistant mutants of M. tuberculosis H37Rv appeared at frequencies of 2 ϫ 10 Ϫ6 to 1 ϫ 10
Ϫ8
. Similar frequencies of fluoroquinolone-resistant mutants have been observed for M. tuberculosis (25, 26) and Mycobacterium smegmatis (23) . Since the MIC of ofloxacin for H37Rv is four times that of ciprofloxacin, the selecting concentrations of ofloxacin are 1, 2, and 4 times the MIC, in comparison with 4, 8, and 16 times the MIC of ciprofloxacin. Therefore, it is remarkable that the frequencies of resistant mutants were no higher with ofloxacin than with ciprofloxacin at each of the three concentrations. With sparfloxacin, it is noteworthy that at 8 g/ml (16 times the MIC) we could detect no resistant mutants.
For the spontaneous fluoroquinolone-resistant mutants obtained in the one-step selection on agar medium containing various concentrations of fluoroquinolones, ciprofloxacin and ofloxacin MICs were as high as 16 g/ml and sparfloxacin MICs were 4 to 8 g/ml. Single-step mutants of M. smegmatis for which MICs are similar have been described previously (23) , although sequential serial-step selection was needed to obtain M. tuberculosis mutants with such levels of fluoroquinolone resistance (25) . Clinical studies with either ofloxacin alone or ofloxacin with other second-line antituberculosis agents in the treatment of tuberculosis resulted in the ready selection of ofloxacin-resistant mutants (4, 12, 22, 27) . This also appears to be the case in the treatment of the two patients from whom our fluoroquinolone-resistant clinical isolates of M. tuberculosis were obtained. Both of these patients had been exposed to a fluoroquinolone as part of their therapy prior to the development of resistance.
Our fluoroquinolone-resistant mutants and clinical isolates displayed cross-resistance to all of the fluoroquinolones tested, with sparfloxacin and one of the investigational fluoroquinolones, FQ-A (PD127391-0002), being the most potent. However, no concomitant development of resistance to isoniazid or rifampin was found.
Analysis of the QRDRs of gyrA genes from all of the fluoroquinolone-resistant strains showed mutations resulting in a substitution of Ala-83 or Asp-87. These are two of the positions at which mutations have been most frequently associated with resistance to fluoroquinolones in other bacterial species (11, 14, 30) . In the strains of M. tuberculosis that we examined, substitution at position Asp-87 (Asp-94 elsewhere [25] ) was the most common, as reported previously for fluoroquinoloneresistant strains of M. tuberculosis (25) . The substitutions observed at this position, asparagine or alanine, were among those noted in fluoroquinolone-resistant strains of M. tuberculosis (4, 25) and M. smegmatis (23) .
M. tuberculosis, M. smegmatis, and M. avium have alanine residues at position 83 in the region of the A subunit of DNA gyrase corresponding to the QRDR (5, 23, 25) rather than serine or threonine, which are present at this site in the majority of reported sequences (14) . It has been suggested that the presence of Ala-83 makes an organism moderately less susceptible to ciprofloxacin (14) , although other differences among bacterial species may contribute to differential susceptibilities. Certain mutational replacements at position 83 have often been reported in fluoroquinolone-resistant mutants of various bacteria (14, 30) , and such is the case with M. tuberculosis, M. smegmatis, and M. avium (5, 23, 25) . It is of interest that the Ala-833Val mutation in M. tuberculosis resulted in a somewhat lower level of fluoroquinolone resistance than that observed with mutations at position 87.
The wild-type parental strain and the spontaneous mutants of H37Rv displayed serine residues at position 88, whereas the clinical isolates had threonine residues at this position. This may represent a naturally occurring nonfunctional polymorphism (25) .
It is unlikely that mechanisms of resistance other than those from the observed mutations could explain the development of resistance in the mutants obtained from a single-step selection. However, the observed fluoroquinolone resistance in the two clinical isolates may be due not only to mutations in the QRDR of gyrA but perhaps also to other mutations affecting DNA gyrase or the permeabilities of the cells to fluoroquinolones (31). In conclusion, broad resistance to fluoroquinolones arose readily in M. tuberculosis H37Rv. Although resistance to fluoroquinolones so far is infrequent in clinical isolates of M. tuberculosis (8) , the ease with which resistance arises in this organism may have serious consequences because these agents are increasingly used in the treatment of multidrug-resistant tuberculosis or in the event of treatment failure. Furthermore, the potential selective pressure for fluoroquinolone resistance is considerable in developing countries, where tuberculosis is highly endemic and patients are frequently treated with fluoroquinolones for enteric infections.
